• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。
J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.
2
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.人尿激酶型纤溶酶原激活剂氨基末端片段与U937单核细胞上特定受体的分化增强结合。
Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43. doi: 10.1073/pnas.82.15.4939.
3
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages.培养的人单核细胞-巨噬细胞同时分泌尿激酶原和纤溶酶原激活物特异性抑制剂。
J Exp Med. 1984 Jun 1;159(6):1653-68. doi: 10.1084/jem.159.6.1653.
4
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.人纤溶酶原与尿激酶原之间高亲和力相互作用的表征
Eur J Biochem. 1985 Jul 1;150(1):141-4. doi: 10.1111/j.1432-1033.1985.tb08999.x.
5
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.尿激酶型纤溶酶原激活物受体将蛋白酶的表达极化至迁移单核细胞的前沿,并促进酶抑制剂复合物的降解。
J Cell Biol. 1990 Aug;111(2):783-92. doi: 10.1083/jcb.111.2.783.
6
The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.纤溶酶原系统与细胞表面:同一细胞类型上存在纤溶酶原和尿激酶受体的证据。
J Cell Biol. 1986 Dec;103(6 Pt 1):2411-20. doi: 10.1083/jcb.103.6.2411.
7
The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).一种人角质形成细胞系(HaCaT)的尿激酶型纤溶酶原激活剂受体。
Exp Cell Res. 1994 Oct;214(2):486-98. doi: 10.1006/excr.1994.1286.
8
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.正常及劳氏肉瘤病毒转化的小鼠成纤维细胞中尿激酶型纤溶酶原激活物的受体
Cancer Res. 1985 Feb;45(2):630-6.
9
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.尿激酶受体通过α-2巨球蛋白受体/低密度脂蛋白受体相关蛋白(Lrp)依赖性内化作用。
J Cell Biol. 1995 Dec;131(6 Pt 1):1609-22. doi: 10.1083/jcb.131.6.1609.
10
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.受体结合型尿激酶对1型纤溶酶原激活物抑制剂的可及性
Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32. doi: 10.1073/pnas.86.13.4828.

引用本文的文献

1
Let-7 Family microRNAs Regulate the Expression of the Urokinase-Receptor in Acute Myeloid Leukemia Cells.Let-7家族微小RNA调控急性髓系白血病细胞中尿激酶受体的表达。
Cells. 2025 Apr 22;14(9):623. doi: 10.3390/cells14090623.
2
CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas.CD87 靶向 BiTE 和 CAR-T 细胞能有效抑制侵袭性无功能垂体腺瘤。
Sci China Life Sci. 2024 Oct;67(10):2169-2185. doi: 10.1007/s11427-024-2591-7. Epub 2024 Jul 8.
3
Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.尿激酶型纤溶酶原激活物受体(uPAR)在炎症与疾病中的作用:一种独特的炎症途径激活剂
Biomedicines. 2024 May 24;12(6):1167. doi: 10.3390/biomedicines12061167.
4
Endothelial-specific Enhancer as a Cis Element of Regulation by TNF-alpha, IL-1beta, and VEGF.内皮细胞特异性增强子作为 TNF-α、IL-1β 和 VEGF 调节的顺式元件。
Curr Pharm Des. 2024;30(21):1630-1640. doi: 10.2174/0113816128296376240424072322.
5
Posttranscriptional Regulation of the Plasminogen Activation System by Non-Coding RNA in Cancer.非编码 RNA 对癌症纤溶酶原激活系统的转录后调控
Int J Mol Sci. 2023 Jan 4;24(2):962. doi: 10.3390/ijms24020962.
6
Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.尿激酶受体信号传导对细胞功能的调节:一种机制性观点
Front Cell Dev Biol. 2022 Apr 8;10:818616. doi: 10.3389/fcell.2022.818616. eCollection 2022.
7
The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis.uPA 系统在皮肤纤维化中差异改变成纤维细胞命运和促纤维化能力。
Front Immunol. 2022 Mar 16;13:845956. doi: 10.3389/fimmu.2022.845956. eCollection 2022.
8
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.尿激酶型纤溶酶原激活物受体(uPAR)作为癌症的治疗靶点。
J Transl Med. 2022 Mar 18;20(1):135. doi: 10.1186/s12967-022-03329-3.
9
Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.癌症中针对尿激酶及其受体的治疗策略
Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498.
10
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.

本文引用的文献

1
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.人肺肿瘤和正常肺组织中纤溶酶原激活剂的含量及特性
Cancer Res. 1980 Mar;40(3):841-8.
2
Evidence for membrane association of plasminogen activator activity in mouse macrophages.小鼠巨噬细胞中纤溶酶原激活物活性与膜结合的证据。
Biochem Biophys Res Commun. 1980 May 30;94(2):480-6. doi: 10.1016/0006-291x(80)91256-5.
3
Specific binding of thrombin by human peripheral blood monocytes: possible role in the clearance of activated clotting factors from the circulation.人外周血单核细胞对凝血酶的特异性结合:在从循环中清除活化凝血因子方面的可能作用。
J Lab Clin Med. 1982 Jun;99(6):873-84.
4
Isolation and characterization of urokinase from human plasma.从人血浆中分离和鉴定尿激酶
J Biol Chem. 1982 Mar 25;257(6):3276-83.
5
Structural relationship between human high and low molecular mass urokinase.人高分子量和低分子量尿激酶之间的结构关系
Hoppe Seylers Z Physiol Chem. 1982 Feb;363(2):133-41. doi: 10.1515/bchm2.1982.363.1.133.
6
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
7
Transforming growth factor(s) production enables cells to grow in the absence of serum: an autocrine system.转化生长因子的产生使细胞能够在无血清条件下生长:一种自分泌系统。
Proc Natl Acad Sci U S A. 1982 Jan;79(2):485-9. doi: 10.1073/pnas.79.2.485.
8
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.通过单克隆抗体亲和层析从人胶质母细胞瘤细胞中纯化酶原至纤溶酶原激活剂。
Biochemistry. 1982 Dec 7;21(25):6410-5. doi: 10.1021/bi00268a014.
9
Functional prothrombinase complex assembly on isolated monocytes and lymphocytes.功能性凝血酶原酶复合物在分离的单核细胞和淋巴细胞上的组装。
J Biol Chem. 1983 Jun 25;258(12):7264-7.
10
Chemotactic response of monocytes to thrombin.单核细胞对凝血酶的趋化反应。
J Cell Biol. 1983 Jan;96(1):282-5. doi: 10.1083/jcb.96.1.282.

人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。

A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

作者信息

Vassalli J D, Baccino D, Belin D

出版信息

J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.

DOI:10.1083/jcb.100.1.86
PMID:3880760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2113459/
Abstract

The secretion of plasminogen activators has been implicated in the controlled extracellular proteolysis that accompanies cell migration and tissue remodeling. We found that the human plasminogen activator urokinase (Uk) (Mr 55,000 form) binds rapidly, specifically, and with high affinity to fresh human blood monocytes and to cells of the monocyte line U937. Upon binding Mr 55,000 Uk was observed to confer high plasminogen activator activity to the cells. Binding of the enzyme did not require a functional catalytic site (located on the B chain of the protein) but did require the noncatalytic A chain of Mr 55,000 Uk, since Mr 33,000 Uk did not bind. These results demonstrate the presence of a membrane receptor for Uk on monocytes and show a hitherto unknown function for the A chain of Uk: binding of secreted enzyme to its receptor results in Uk acting as a membrane protease. This localizes plasminogen activation near the cell surface, an optimal site to facilitate cell migration.

摘要

纤溶酶原激活剂的分泌与伴随细胞迁移和组织重塑的可控细胞外蛋白水解有关。我们发现人纤溶酶原激活剂尿激酶(Uk)(55,000分子量形式)能快速、特异性且高亲和力地结合新鲜人血单核细胞及单核细胞系U937的细胞。结合后,观察到55,000分子量的Uk赋予细胞高纤溶酶原激活剂活性。该酶的结合不需要功能性催化位点(位于蛋白的B链上),但确实需要55,000分子量Uk的非催化A链,因为33,000分子量的Uk不结合。这些结果证明单核细胞上存在Uk的膜受体,并揭示了Uk的A链迄今未知的功能:分泌的酶与其受体结合导致Uk作为膜蛋白酶起作用。这将纤溶酶原激活定位在细胞表面附近,这是促进细胞迁移的最佳位点。